Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 2, 2018updated 11 Jan 2018 10:15am

BD concludes $24bn deal with CR Bard

Becton Dickinson (BD) has completed the acquisition of CR Bard for $24bn, under a definitive agreement signed between the companies in April last year.

Becton Dickinson (BD) has completed the acquisition of CR Bard for $24bn, under a definitive agreement signed between the companies in April last year.

Expected to result in annualised revenue of around $16bn, the combined entity aims to improve disease treatment for patients and process of care for healthcare providers.

The deal is said to leverage BD’s expertise in medication management and infection prevention while boosting its growth opportunities with the addition of Bard’s product portfolio and pipeline.

Becton Dickinson chairman and CEO Vincent Forlenza said: “Today is a historic day for BD as we welcome Bard and its 16,000 associates to BD.

“These companies each have a legacy of more than 100 years of advancing the world of health and supporting those on the frontlines of healthcare.

“The deal is said to leverage BD’s expertise in medication management and infection prevention while boosting its growth opportunities.”

“We look forward to continuing to lead the industry through innovation and partnerships that bring more valuable solutions to our customers and their patients.”

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Ensuring quality and supply chain visibility for medical device components

Following the transaction, Bard became a wholly owned subsidiary of BD, which will report the majority of acquired offerings under a new Interventional segment structure.

The firm plans to report the remaining Bard offerings under the Medical division.

Based in the US, Bard develops, manufactures and markets life-enhancing medical technologies for vascular, urology, oncology, and surgical sectors.

The combination of the firm’s vascular access products with BD’s IV drug preparation, dispensing, delivery, and administration will enable the offering of end-to-end medication management solutions.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU